Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (vol 8, e000391, 2020) P. A. Ascierto , M. Del Vecchio , A. Mackiewicz , Caroline Robert , Vanna Chiarion-Sileni , Ana Arance , Celeste Lebbe , Inge Marie Svane , Catriona McNeil , Piotr Rutkowski , Carmen Loquai , Laurent Mortier , Omid Hamid , Lars Bastholt , Brigitte Dreno , Dirk Schadendorf , Claus Garbe , Marta Nyakas , Jean-Jacques Grob , Luc Thomas , Gabriella Liszkay , Michael Smylie , Christoph Hoeller , Virginia Ferraresi , Florent Grange , Ralf Gutzmer , Joanna Pikiel , Fareeda Hosein , Burcin Simsek , Michele Maio JOURNAL FOR IMMUNOTHERAPY OF CANCER（2020）
AI 理解论文
溯源树
样例
